A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer

Gynecologic Oncology
Judith K WolfDavid M Gershenson

Abstract

To determine the efficacy, toxicity, and quality of life of capecitabine (Xeloda), an oral 5-fluorouracil derivative, in patients with chemorefractory recurrent mullerian cancers. Patients with chemorefractory persistent or recurrent ovarian, fallopian tube, or peritoneal cancer with measurable disease were enrolled. Capecitabine was administered beginning at 2000 mg/m2/day orally in two divided doses with meals on a 21-day cycle: 14 days of capecitabine followed by a 7-day rest period. One dose escalation or reduction was allowed. Response was assessed after cycle 2 and cycle 4 and every third cycle thereafter. Standard evaluation included two-dimensional measurement of evaluable disease. Standard criteria for response were used. Therapy was discontinued if progression occurred after at least two cycles of therapy. Quality of life and symptoms were assessed. Forty-one patients were enrolled. Ninety-two percent of patients had >2 previous chemotherapy regimens. All patients had platinum- and taxane-resistant disease. Thirty-six patients were evaluable for response. Three patients had a partial response, with a median response duration of five cycles. Twenty-two patients had stable disease for 3 to 11 cycles (median, 6 cycles). ...Continue Reading

References

Mar 1, 1989·Controlled Clinical Trials·R Simon
Oct 19, 1994·Journal of the National Cancer Institute·B LundJ P Neijt
Jan 1, 1994·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R K PortenoyL Norton
May 1, 1996·Gynecologic Oncology·M PréfontaineL Buley
Mar 30, 2001·Gynecologic Oncology·P SørensenK Bertelsen
Jan 5, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Thomas H CartwrightJoseph J Schulz
Apr 19, 2002·The Oncologist·Andrew Bottomley
Jan 15, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Diane C BodurkaDavid M Gershenson
Jul 26, 2003·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P ReichardtH J Lück
Dec 8, 2004·Gynecologic Oncology·Mace L RothenbergDavid S Alberts

❮ Previous
Next ❯

Citations

Jul 10, 2014·Journal of the National Cancer Institute·Kristine A DonovanLari Wenzel
Sep 8, 2010·Expert Opinion on Investigational Drugs·Koji MatsuoAnil K Sood
Apr 14, 2009·Gynecologic Oncology·David M GershensonJohn J Kavanagh
Oct 20, 2009·European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society·Nesrin ReisAnahit Coskun

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.